DNA microarray analysris: New drug targets for myasthenia gravis

Tali Feferman; Revital Aricha; P. K. Maiti; G. Clairac; M. Cuvelier; S. Berrih-Aknin; Shai Fuchs; M. C. Souroujon

DNA microarray analysris: New drug targets for myasthenia gravis

Tali Feferman, Revital Aricha, P. K. Maiti, G. Clairac, M. Cuvelier, S. Berrih-Aknin, Shai Fuchs, M. C. Souroujon

Research output: Contribution to conference › Paper › peer-review

Abstract

Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG) are autoimmune disorders in which the acetylcholine receptor (AChR) is the major autoantigen. DNA microarray technology, supported by quantitative real time PCR, immunohistochemistry and flow cytometry, were used to identify new potential drug targets for the treatment of MG and to delineate genes involved in the pathogenesis of the disease. We have compared gene expression in lymph node cells (LNC) and muscles of rats with EAMG to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG we chose to elaborate on the chemokine IFN-gamma-inducible protein 10 (IP-10, CXCL10), and its receptor CXCR3 and on phospodiesterases (PDEs).

Original language	English
Pages	163-166
Number of pages	4
Publication status	Published - Sept 2006
Event	8th International Congress of Neuroimmunology - Nagoya, Japan Duration: 15 Oct 2006 → 19 Oct 2006 Conference number: 8th

Conference

Conference	8th International Congress of Neuroimmunology
Country/Territory	Japan
City	Nagoya
Period	15/10/06 → 19/10/06

Bibliographical note

NA

Cite this

@conference{7b25f031672d432da807cefa149b2f46,

title = "DNA microarray analysris: New drug targets for myasthenia gravis",

abstract = "Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG) are autoimmune disorders in which the acetylcholine receptor (AChR) is the major autoantigen. DNA microarray technology, supported by quantitative real time PCR, immunohistochemistry and flow cytometry, were used to identify new potential drug targets for the treatment of MG and to delineate genes involved in the pathogenesis of the disease. We have compared gene expression in lymph node cells (LNC) and muscles of rats with EAMG to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG we chose to elaborate on the chemokine IFN-gamma-inducible protein 10 (IP-10, CXCL10), and its receptor CXCR3 and on phospodiesterases (PDEs).",

author = "Tali Feferman and Revital Aricha and Maiti, {P. K.} and G. Clairac and M. Cuvelier and S. Berrih-Aknin and Shai Fuchs and Souroujon, {M. C.}",

note = "NA; 8th International Congress of Neuroimmunology ; Conference date: 15-10-2006 Through 19-10-2006",

year = "2006",

month = sep,

language = "English",

pages = "163--166",

}

TY - CONF

T1 - DNA microarray analysris

T2 - 8th International Congress of Neuroimmunology

AU - Feferman, Tali

AU - Aricha, Revital

AU - Maiti, P. K.

AU - Clairac, G.

AU - Cuvelier, M.

AU - Berrih-Aknin, S.

AU - Fuchs, Shai

AU - Souroujon, M. C.

N1 - Conference code: 8th

PY - 2006/9

Y1 - 2006/9

N2 - Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG) are autoimmune disorders in which the acetylcholine receptor (AChR) is the major autoantigen. DNA microarray technology, supported by quantitative real time PCR, immunohistochemistry and flow cytometry, were used to identify new potential drug targets for the treatment of MG and to delineate genes involved in the pathogenesis of the disease. We have compared gene expression in lymph node cells (LNC) and muscles of rats with EAMG to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG we chose to elaborate on the chemokine IFN-gamma-inducible protein 10 (IP-10, CXCL10), and its receptor CXCR3 and on phospodiesterases (PDEs).

AB - Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG) are autoimmune disorders in which the acetylcholine receptor (AChR) is the major autoantigen. DNA microarray technology, supported by quantitative real time PCR, immunohistochemistry and flow cytometry, were used to identify new potential drug targets for the treatment of MG and to delineate genes involved in the pathogenesis of the disease. We have compared gene expression in lymph node cells (LNC) and muscles of rats with EAMG to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG we chose to elaborate on the chemokine IFN-gamma-inducible protein 10 (IP-10, CXCL10), and its receptor CXCR3 and on phospodiesterases (PDEs).

M3 - Paper

SP - 163

EP - 166

Y2 - 15 October 2006 through 19 October 2006

ER -

DNA microarray analysris: New drug targets for myasthenia gravis

Abstract

Conference

Bibliographical note

Fingerprint

Cite this